Browse > Article

Discrepancy of Bone Metastases between F-18 FDG PET/CT and Bone Scan in a Patient with Prostate Cancer  

Choi, Seung-Jin (Department of Nuclear Medicine, Inha University College of Medicine)
Kim, Chul-Soo (Department of International Medicine, Inha University College of Medicine)
Byun, Sung-Su (Department of Radiology, Inha University College of Medicine)
Hyun, In-Young (Department of Nuclear Medicine, Inha University College of Medicine)
Publication Information
Nuclear Medicine and Molecular Imaging / v.40, no.5, 2006 , pp. 275-278 More about this Journal
Abstract
We report the case of a 73-year-old man who had prostate cancer with bone metastases. Tc-99m HDP Whole body bone scan revealed multiple areas of increased bony uptake consistent with widespread bone metastases. F-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) demonstrated mild F-18 FDG uptake in the lymph nodes of neck, abdomen, and pelvis. However, abnormal F-18 FDG uptake was not seen in the skeletal system. Biopsy and immunohistochemical stains of left supraclavicular mass showed metastatic prostate adenocarcinoma. Currently, there are a few reported cases of F-18 FDG PET/CT evaluation of bone metastases in prostate cancer. We discuss the discrepancy between F-18 FDG PET/CT and bone scan in the detection of osseous metastases of prostate cancer.
Keywords
osseous metastases; bone scan; F-18 FDG PET/CT; prostate cancer;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Ghanem N, Uhl M, Brink I, Schafer O, Kelly T, Moser E, et al. Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of bone. Eur J Radiol 2005;55:41-55   DOI   ScienceOn
2 Nakamoto Y, Osman M, Wahl RL. Prevalence and patterns of bone metastases detected with positron emission tomography using F-18 FDG. Clin Nucl Med 2003;28:302-7   DOI
3 Cook GJ, Houston S, Rubens R, Maisey MN, Fogelman I. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 1998;16:3375-9   DOI
4 O'Sullivan JM, Cook GJR. A review of the efficacy of bone scanning in prostate and breast cancer. Q J Nucl Med 2002; 46:152-9
5 Peterson JJ, Kransdorf MJ, O'Connor MI. Diagnosis of occult bone metastases: positron emission tomography. Clin Orthop Relat Res 2003;415s:s120-8   DOI
6 Yang SN, Liang JA, Lin FJ, Kao CH, Lin CC, Lee CC. Comparing whole body (18)F-2-deoxyglucose positron emission tomography and technetinm-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer. J Cancer Res Clin Oncol 2002;128:325-8   DOI
7 Shreve PD, Grossman HB, Gross MD, Warl RL. Metastatic prostate cancer: initial finding of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology 1996;199:751-6   DOI